Inside J&J’s Atraverse Medical Acquisition

Johnson & Johnson’s agreement to acquire Atraverse Medical fits a pattern that has become increasingly familiar across medtech M&A. Strategic buyers are continuing to target commercial-stage companies operating in expanding procedural markets where workflow advantages and ecosystem positioning matter just as much as the core technology itself.

This deal also highlights something else: the founders behind FARAPULSE have once again identified a procedural bottleneck inside the same operating room and built a company around solving it. Steven Mickelsen, John Slump, Eric Sauter, and their broader team previously helped reshape pulsed-field ablation before Boston Scientific acquired FARAPULSE in 2021. Now, they have built a left-heart access platform that Johnson & Johnson believes strengthens Biosense Webster’s position in EP.

The timing is important. So is the strategic fit. 

J&J’s Structural Advantage in EP

Johnson & Johnson’s electrophysiology (EP) business is not simply large. It is deeply embedded in the clinical workflow through Biosense Webster and the CARTO mapping platform.

Today, Biosense Webster controls more than 40% of the U.S. EP ablation catheter market and roughly 60% globally. Much of that position is tied directly to the widespread adoption of CARTO, which has remained the leading cardiac mapping system for decades. More than 5,000 systems are now installed worldwide.

That installed base creates a powerful commercial foundation. Every new EP technology integrated into the Biosense Webster portfolio immediately benefits from existing physician familiarity, procedural integration, and access to established hospital infrastructure.

That is where HOTWIRE enters the picture.

Why Atraverse Medical Matters

Atraverse developed HOTWIRE to simplify transseptal access, a critical step in left-heart procedures used to treat atrial fibrillation and other arrhythmias. Physicians must cross from the right atrium into the left atrium before ablation can begin, making this one of the foundational steps in nearly every left-heart ablation procedure.

It is also one of the most technically sensitive portions of the workflow.

Conventional RF guidewires continuously deliver energy during septal crossing. Once the wire enters the left atrium, there is potential for unintended tissue injury. Existing approaches can also introduce procedural inefficiencies, including sheath exchanges, inconsistent crossing forces, and risk of dilator skiving and emboli creation.

HOTWIRE was designed specifically to address those issues. Its impedance-guided RF generator automatically stops energy delivery once left atrial entry is detected. It is currently the only device with that capability.

Clinical performance data have reinforced the value proposition. A multicenter first-in-human study involving roughly 500 patients demonstrated 100% procedural success. Data presented at the 2026 European Heart Rhythm Association meeting showed a 0% incidence of unintended left atrial injury, compared to rates exceeding 50% observed with other RF guidewires in comparative studies.

The workflow benefits are equally important:

  • Zero-exchange functionality that acts as both the crossing tool and support rail
  • Increased stiffness relative to competing systems for improved large-bore sheath support
  • Universal sheath compatibility that avoids forcing physicians into new procedural workflows

These types of improvements matter in high-volume AFib programs where complication reduction, procedural efficiency, and downstream cost control directly affect operational performance.

Since receiving FDA 510(k) clearance in 2024, the device has already been used in approximately 3,000 procedures as part of a limited market release. The company achieved that traction with roughly $40 million in funding and in under four years of operation.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/inside-jjs-atraverse-medical-acquisition

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more